|
|
Gilead Avoided $10 Billion In Taxes On Over Priced Hepatitis C Drugs
Smallteacher, Richard http://www.corpwatch.org/article.php?id=16083
Publisher: CorpWatch
Date Written: 13/07/2016
Year Published: 2016
Resource Type: Article
A new drug called Sovaldi, intended to treat Hepatitis C, is incredibly unaffordable and inaccessible for Americans.
Abstract: -
Excerpt:
Today, Gilead charges U.S. customers $84,000 for a full 12 week course of Solvadi even though the actual manufacturing costs are estimated to fall somewhere between between $68 and $1,400. Gilead also sells a combination drug package known as Harvoni at $94,500 for a full treatment.
...
But the stock market has sent the company's share price soaring to four times the book value when it bought up Pharmasset five years ago.
..
Ironically, Gilead sells Sovaldi for much less outside the U.S.. including in Ireland. A full course in the U.K. costs $57,000 and just $900 in Schinazi's native Egypt.
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
